neurofibromatosis

DEFINITION of neurofibromatosis

neurofibromatosis is a group of autosomal dominant genetic disorders that cause tumors to develop on nerve tissue, producing lesions called neurofibromas in the skin, peripheral nerves, and central nervous system. It differs from an isolated Schwannoma or Neuroma in that neurofibromatosis is a systemic, multi-tumor genetic syndrome rather than a single sporadic nerve-sheath tumor. The underlying mechanism is loss-of-function mutation in a tumor-suppressor gene — NF1 on chromosome 17 (encoding neurofibromin) for type 1, or NF2 on chromosome 22 (encoding merlin/schwannomin) for type 2 — resulting in unchecked Schwann cell, fibroblast, and perineural cell proliferation. neurofibromatosis is always pathological; it is not a normal physiological process. Clinically relevant subtypes coded separately include neurofibromatosis, type 1 (Q85.01), neurofibromatosis, type 2 (Q85.02), and Schwannomatosis (Q85.03), each with distinct tumor patterns and surveillance needs. NF1 is distinguished from NF2 by its hallmark café-au-lait macules, Lisch nodules, and optic pathway gliomas, whereas NF2 is defined by bilateral vestibular schwannomas and a much lower incidence of cutaneous findings.

---

ETYMOLOGY of neurofibromatosis

greek | latin

Component	Origin	Meaning
neuro-	Greek neuron (νεῦρον)	“nerve,” “sinew” — combining form denoting nerve tissue
fibr-	Latin fibra	”fiber,” “filament” — combining form denoting fibrous connective tissue
-oma	Greek -oma (-ωμα)	Noun-forming suffix — “tumor,” “morbid growth”
-osis	Greek -osis (-ωσις)	Noun-forming suffix — “abnormal condition,” “increase,” “process”

The term entered medical English in the late 19th century as neurofibromatosis (noun), a compound coined from neuro- + fibroma + -osis to describe the eponymous condition first systematically described by German pathologist Friedrich Daniel von Recklinghausen in 1882. The root -oma (“tumor”) links neurofibromatosis to the broader family of nerve-tissue tumors: neuroma (nerve + tumor → benign nerve growth), schwannoma (Schwann cell + tumor → tumor of the nerve sheath), and glioma (glia- + tumor → tumor of glial support cells). The suffix -osis is highly productive in medical terminology, appearing in fibrosis, stenosis, necrosis, and thrombosis.

---

🔀 ALIASES / ALTERNATE TERMS

• Neurofibromatous (adjective form — e.g., “neurofibromatous nodules,” “neurofibromatous degeneration”)
• Von Recklinghausen disease (historical eponym, used specifically for NF1; coded to Q85.01)
• NF1 / Peripheral neurofibromatosis (type 1; the more common form, ~90% of cases; Q85.01)
• NF2 / Central neurofibromatosis / Bilateral acoustic neurofibromatosis (type 2; defined by bilateral vestibular schwannomas; Q85.02)
• Schwannomatosis (sometimes historically called “NF3”; now a distinct, separately coded entity; Q85.03)

---

🔗 RELATED TERMS

• Schwannoma — a benign nerve-sheath tumor composed purely of Schwann cells; distinguished from a neurofibroma, which contains a mixture of Schwann cells, fibroblasts, and perineural cells within the nerve.
• Neuroma — shares the neuro- root; a general term for any benign nerve-tissue growth, which may be traumatic (post-transection) or tumor-related, unlike the genetically driven tumors of neurofibromatosis.
• Plexiform neurofibroma — a locally invasive neurofibroma subtype that grows along multiple nerve fascicles/branches, characteristic of NF1 and carrying a small risk of malignant transformation.
• Lisch nodules — pigmented iris hamartomas, an ophthalmologic hallmark finding used in the clinical diagnostic criteria for NF1.
• Optic glioma — a low-grade astrocytoma of the optic pathway occurring in a subset of NF1 patients, distinct from the peripheral nerve tumors of NF1 but part of the same syndrome.
• Vestibular schwannoma — a schwannoma of the vestibulocochlear (CN VIII) nerve; bilateral vestibular schwannomas are the defining diagnostic feature of NF2.
• Neurofibromin — the tumor-suppressor protein product of the NF1 gene; its loss drives unregulated Ras-pathway signaling and tumor growth in type 1 disease.
• Merlin (schwannomin) — the tumor-suppressor protein product of the NF2 gene; its loss drives Schwann cell proliferation in type 2 disease and schwannomatosis.
• Café-au-lait macule — a flat, hyperpigmented skin lesion; multiple lesions (≥6) are a major diagnostic criterion for NF1, not a coded entity on its own.

---

CODING CORNER

🏥 ICD-10-CM CODES

Neurofibromatosis (Q85.0- — No Laterality Required)

Code	Description
Q85.00	Neurofibromatosis, unspecified
Q85.01	Neurofibromatosis, type 1
Q85.02	Neurofibromatosis, type 2
Q85.03	Schwannomatosis
Q85.09	Other neurofibromatosis

---

🔧 COMMON CPT CODES (Neurofibromatosis-Related Diagnosis & Treatment)

CPT Code	Description
92225	Ophthalmoscopy, extended, with retinal drawing and scleral depression, initial (used to evaluate for Lisch nodules/optic pathway involvement)
92557	Comprehensive audiometry threshold evaluation and speech recognition (baseline/surveillance for NF2-related hearing loss)
92585	Auditory evoked potentials for evoked response audiometry (used in vestibular schwannoma screening for NF2)
70551	MRI brain without contrast (surveillance imaging for optic glioma or vestibular schwannoma)
70553	MRI brain without contrast, followed by contrast and further sequences (standard protocol for NF2 tumor surveillance)
61510	Craniectomy/craniotomy for excision of brain tumor, supratentorial (used for symptomatic NF2-related intracranial schwannoma)
11406	Excision, benign lesion, trunk/arms/legs, excised diameter over 4.0 cm (cutaneous/subcutaneous neurofibroma excision)
64788	Excision of neuroma, cutaneous nerve (surgical debulking of a symptomatic peripheral neurofibroma)
81408	Molecular pathology procedure, Level 9 (used for NF1/NF2 full gene sequencing to confirm diagnosis)

---

⚠️ Coding Note: Q85.0- codes do not require laterality, but they do require type specificity — never default to Q85.00 (unspecified) when the documentation supports NF1, NF2, or schwannomatosis, since type distinction drives surveillance protocols and HCC risk-adjustment weighting differently. Sequence the Q85.0- code first, followed by manifestation codes for associated neoplasms (e.g., optic glioma, vestibular schwannoma) coded separately per ICD-10-CM neoplasm table guidance — the manifestation is never combined into the Q85.0- code itself. Watch for documentation trigger phrases like “café-au-lait spots,” “acoustic neuroma,” or “family history of NF” without a stated type — these should prompt a physician query to specify NF1 vs. NF2 vs. schwannomatosis rather than defaulting to unspecified. Genetic testing CPT codes (e.g., 81408) frequently require payer prior authorization, so confirm medical necessity documentation (family history, clinical diagnostic criteria met) is present before claim submission.

---

DERIVATIONS of neurofibromatosis

TABLE definition AS Definition
FROM #medterm 
WHERE length(filter(roots, (word) => econtains([[Neurofibromatosis]].roots, word))) > 0 AND file.name != [[Neurofibromatosis]].file.name
SORT file.name ASC

---

Query functionality

TABLE definition AS Definition
FROM #medterm 
WHERE length(filter(definition, (word) => econtains([[Neurofibromatosis]].definition, word))) > 0 AND file.name != [[Neurofibromatosis]].file.name

Med terms dictionary Appendix A Prefixes Appendix B Combining Forms Appendix C Suffixes Appendix D Suffix forms